Triamcinolone acetonide is a generic topical steroid intended to treat inflammation caused by various skin conditions, including allergic reactions, eczema and psoriasis.
The topical cream represents Teligent’s fifth approval this year and sixteenth approval from its internal pipeline of topical generic drugs.
Teligent will launch the triamcinolone acetonide cream in the fourth quarter of 2017.
More articles on supply chain:
Biosimilars are getting approved, but few have hit the market — here’s why
6 drugmakers in the headlines
FDA approves treatment for common gynecologic infection: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
